Accord Healthcare, Inc., a US-based generic pharmaceutical company, announced on Wednesday that it has added Bendamustine Lyo. Injection to its range of chemotherapy drugs.

The company's product is AP rated to Teva's Treanda and is available in both 25-mg and 100-mg vials.

The product is in a class of medications called alkylating agents and works by killing existing cancer cells and limiting the growth of new cancer cells. The product is intended to treat adults with chronic lymphocytic leukaemia (CLL) or indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or rituximab containing regimen.

Accord Healthcare resident Jeff Hampton, said, 'Adding Bendamustine Lyo. Injection to our line of available chemotherapy drugs is an important step in continuing to make oncology therapies more accessible to those who need them. The availability of generics expands medication options for patients. When pharmacists have access to additional manufacturers, they are able to offer needed oncology products at a lower cost.'